Watson Pharmaceuticals

Watson Pharmaceuticals Acquires Uteron Pharma SA

The pharmaceutical firm’s acquisition is aimed to expand its pipeline of women’s health products.

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential future milestone payments.  The acquisition of Uteron expands Watson's Global Brands pipeline of Women's Health products including two potential near term global commercial opportunities in contraception and infertility, and one novel oral contraceptive, projected to launch globally in 2018.  Several additional products in earlier stages of development are also included in the acquisition.

Your rating: None Average: 5 (1 vote)

Watson's Generic Version of Pulmicort RESPULES Receives FDA Approval

The company has received the go-ahead for the treatment, intended to treat asthma symptoms in children.

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca's Pulmicort RESPULES. Watson is currently involved in patent litigation with AstraZeneca concerning this product.

No votes yet

FDA Approves Watson’s Generic Version of Plan B One-Step

Watson Pharmaceuticals has received the go-ahead to launch its generic version of the emergency contraceptive.

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice™ ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.

No votes yet
Syndicate content